Cytomegalovirus infection and coronary heart disease: Results of a German case-control study

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 690-692

  Rothenbacher, D ^a   Hoffmeister, A ^a   Bode, G ^a   Wanner, P ^a   Koenig, W ^a   Brenner, H ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GERMANY; HUMAN; HUMAN CYTOMEGALOVIRUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; BLOOD VISCOSITY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FIBRINOGEN; GERMANY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTE COUNT; MALE; MIDDLE AGED; ODDS RATIO;

EID: 0033386730     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314634     Document Type: Article

References (14)

1. 1. Bodurtha J, Adler SP, Nance WE. Scroepidemiology of cytomegalovirus and herpes simplex virus in twins and their families. Am J Epidemiol 1988; 128:268-76.
2. 2. Peterslund NA. Herpesvirus infection: an overview of the clinical manifestations. Scand J Infect Dis Suppl 1991;80:15-20.
3. 3. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Athero-arteriosclerosis induced by infection with a herpesvirus. Am J Pathol 1979;96:673-706.
4. 4. Van Dam-Mieras MC, Bruggeman CA, Muller AD, Debie WH, Zwaal RF. Induction of endothelial cell procoagulant activity by cytomegalovirus infection. Thromb Res 1987;47:69-75.
5. 5. Danesh J, Collins R, Peto R. Chronic infection and coronary heart disease: is there a link? Lancet 1997;350:430-6.
6. 6. Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998;177:209-12.
7. 7. Adam E, Probstfield JL, Burek J, et al. High levels of cytomegalovirus antibodies in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-3.
8. 8. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996;348:S13-7.
9. 9. Zbou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-30.
10. 10. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
11. 11. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
12. 12. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
13. 13. Nieto FJ, Sorlie P, Comstock GW, et al. Cytomegalovirus infection, lipo-protein(a), and hypercoagulability: an atherogenic link? Arterioscler Thromb Vasc Biol 1997;17:1780-5.
14. 14. Peckham CS. Cytomegalovirus infection: congenital and neonatal disease. Scand J Infect Dis Suppl 1991;80:82-7.